Search
Urogen Pharma Ltd
URGNAdd to Watchlist
43.490USD
+1.750+4.19%
Close 09-16 16:00（ET）
2.13BMarket Cap
LossP/E TTM
Urogen Pharma Ltd (URGN) Stock Price Target & Forecast
Analyst Rating
Based on 8 analysts giving stock ratings to Urogen Pharma Ltd in the past month.
Buy
4 Strong Buy
3 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
60.000USD+43.75%
URGN Analyst Recommendation Trends
In the current month, URGN has received 3 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. URGN average Analyst price target in the last month is 60.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
4
4
4
4
3
3
3
3
3
3
3
3
4
4
4
4
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
8
8
8
8
8
8
8
URGN Analyst Rating for Peer Comparison
Updated: Sep 16, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Ascendis Pharma A/S
ASND
10
10
0
0
0
20
Financial Forecasting
Based on analysts' estimates, URGN EPS is projected to reach 0.127 in FY2026Q3, following reported EPS of -0.285 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.50
-0.48
-0.29
0.13
0.46
Actual
-0.54
-0.47
-0.28
--
--
Surprise
-6.56%
+2.64%
+0.80%
--
--
FAQs
What is Urogen Pharma Ltd's expected revenue for the next quarter?
Urogen Pharma Ltd's expected revenue is 90.58M.
What is Urogen Pharma Ltd's price target?
Analysts forecast that Urogen Pharma Ltd's price target is USD 60.00, with the highest forecast at USD 75.00 and the lowest forecast at USD 48.00.
How have Urogen Pharma LtdURGN's recent earnings per share performed?
The market expectation was USD -0.28, while Urogen Pharma LtdURGN's earnings per share (EPS) for the previous quarter was USD -0.47. EPS for the next quarter is expected at USD 0.13.
What is the analyst rating for Urogen Pharma Ltd?
Based on the ratings of Urogen Pharma Ltd's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.